Back to top

vaccines: Archive

Zacks Equity Research

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.

SNYPositive Net Change NVAXNegative Net Change BEAMPositive Net Change ADPTPositive Net Change

Zacks Equity Research

Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.

SNYPositive Net Change NVAXNegative Net Change CTMXNegative Net Change ARGXPositive Net Change

Zacks Equity Research

Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance

GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.

SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change

Shaun Pruitt

Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?

Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.

PFEPositive Net Change JNJPositive Net Change NVOPositive Net Change LLYNegative Net Change ABBVNegative Net Change

Zacks Equity Research

AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.

SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change AMGNNegative Net Change

Zacks Equity Research

GSK to Report First-Quarter Earnings: Is a Beat in Store?

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

GSKPositive Net Change JNJPositive Net Change CTMXNegative Net Change ARGXPositive Net Change

Zacks Equity Research

Can Moderna Keep the Beat Streak Alive This Earnings Season?

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

MRKPositive Net Change MRNAPositive Net Change CTMXNegative Net Change ARGXPositive Net Change